EMA Authorised: Aclasta (zoledronic acid) — Sandoz Pharmaceuticals d.d.

View source ↗

Summary

The EMA authorised Sandoz's Aclasta (zoledronic acid) for osteoporosis indications, including postmenopausal osteoporosis and Paget disease of bone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Paget Disease of Bone
• Postmenopausal Osteoporosis

Drugs mentioned

• Aclasta (zoledronic acid)

Snippet

Status: Authorised. Therapeutic area: Osteoporosis;Osteitis Deformans;Osteoporosis, Postmenopausal. MAH: Sandoz Pharmaceuticals d.d.. Decision date: 16/04/2026